Parker S S, Choo-Kang Y F, Cooper E J, Cameron S J, Grant I W
Br Med J. 1971 Oct 16;4(5780):139-42. doi: 10.1136/bmj.4.5780.139.
In a double-blind trial the effect on ventilatory function of oral salbutamol (in two different doses) and a placebo were studied in 12 patients with chronic asthma receiving regular maintenance treatment with prednisolone. Salbutamol in a dose of 4 mg four times daily, given for a period of four weeks, produced a sustained and statistically significant increase in peak expiratory flow rate over the pretreatment recordings. This effect was not observed with a lower dose of salbutamol (2 mg four times daily) or with a placebo. Salbutamol in the higher dose would seem to be an effective and safe oral bronchodilator that can be recommended for the treatment of mild or moderate asthma. The duration of treatment in this study was, however, limited to four weeks, and it is not known whether effective bronchodilatation would be maintained if the drug were given for longer periods.
在一项双盲试验中，对12名接受泼尼松龙常规维持治疗的慢性哮喘患者，研究了口服沙丁胺醇（两种不同剂量）和安慰剂对通气功能的影响。每日4次，每次4毫克的沙丁胺醇，给药4周，与治疗前记录相比，呼气峰值流速持续且有统计学意义地增加。较低剂量的沙丁胺醇（每日4次，每次2毫克）或安慰剂未观察到这种效果。较高剂量的沙丁胺醇似乎是一种有效且安全的口服支气管扩张剂，可推荐用于治疗轻度或中度哮喘。然而，本研究的治疗持续时间限于4周，尚不清楚如果长期给药，是否能维持有效的支气管扩张作用。
